CN102100666A - New moxifloxacin hydrochloride injection - Google Patents
New moxifloxacin hydrochloride injection Download PDFInfo
- Publication number
- CN102100666A CN102100666A CN 201110008974 CN201110008974A CN102100666A CN 102100666 A CN102100666 A CN 102100666A CN 201110008974 CN201110008974 CN 201110008974 CN 201110008974 A CN201110008974 A CN 201110008974A CN 102100666 A CN102100666 A CN 102100666A
- Authority
- CN
- China
- Prior art keywords
- injection
- moxifloxacin hydrochloride
- moxifloxacin
- special solvent
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicament, namely moxifloxacin hydrochloride injection for treating or preventing human or animal bacteria infection, and application of a preparation in regulation of physiological isotonic osmotic pressure of the moxifloxacin hydrochloride injection.
Description
Technical field:
The invention belongs to medical technical field, relate to a kind of medicine that is used for the treatment of or prevents human or animal's bacterial infection, especially the moxifloxacin hydrochloride injection.
Technical background:
Moxifloxacin (Moxifloxacin) is the novel fluoroquinolone antibiotics that Bayer company develops in recent years, can act on gram positive bacteria and gram negative bacteria effectively, strong to staphylococcus aureus, streptococcus and enterococcal specific activity ciprofloxacin, tubercule bacillus also there is stronger effect.
The antibacterial action mechanism of Moxifloxacin is for disturbing II, IV topoisomerase.Topoisomerase is the key enzyme of control DNA topological sum at dna replication dna, in repairing and transcribing.Its killing curve shows that the bactericidal activity of Moxifloxacin has concentration dependent, its minimum bactericidal concentration and minimum inhibitory concentration basically identical.Moxifloxacin is also effective to beta-lactam class and the drug-fast antibacterial of macrolide antibiotics.Confirm that by the experimental animal model that infects the activity in vivo of Moxifloxacin is higher.
The Moxifloxacin preparation of Beyer Co., Ltd's listing mainly is moxifloxacin hydrochloride tablet and injection.The moxifloxacin hydrochloride tablet was registered in Mexico first in February, 1999, and in JIUYUE, 1999 is in German Initial Public Offering, injection in calendar year 2001 December respectively in the U.S. and Germany's listing, be tablet and injection in China's listing dosage form at present.The structural formula of moxifloxacin hydrochloride is as follows:
For the treatment of those intensive care patient, because can not oral administration, the exploitation that therefore can carry out the injection of parenteral seems very necessary.For a kind of acceptable transfusion, its osmotic pressure must be adjusted to the organism physiology level, the most frequently used osmotic pressure regulator comprises sodium chloride, glucose, mannitol etc.Beyer Co., Ltd has just protected the sodium chloride of relative broad range as osmotic pressure regulator at Chinese patents ZL00811427.7; but it also spells out; the dissolubility of moxifloxacin hydrochloride is too poor in the presence of sodium chloride; to such an extent as to after precipitation forms; once once abandoned the preparation of exploitation moxifloxacin hydrochloride, reactive compound and a certain amount of sodium chloride of finally having to use narrow concentration range have prepared the agent of acceptable Moxifloxacin hydrochlorate large capacity transfusion as isoosmotic adjusting agent.The dosage form of list marketing is the sodium chloride infusion solutions of 250ml.Be that sodium chloride is 0.9% infusion solutions for the first time when China applies for the registration of, change to 0.8% infusion solutions for the second time.Can fully find out, Beyer Co., Ltd for improve active component in sodium chloride transfusion dissolubility and reduced the isoosmotic requirement of physiology, measure through the osmotic pressure value that we carry out the transfusion of three lot numbers of Bayer listing, its osmotic pressure has only 280m0smol/kg, rigidly connects the lower limit of the osmotic pressure molar density scope of nearly normal human's blood.Simultaneously we at 25 ℃, the saturation solubility in the sodium chloride solution of different content is measured respectively for moxifloxacin hydrochloride, the result is as shown in table 1.Experimental data by this table we draw the dissolubility of moxifloxacin hydrochloride in the solution of sodium chloride-containing not will be apparently higher than the solution of sodium chloride-containing.
Table 1 moxifloxacin hydrochloride dissolubility
Patent ZL00811427.7 also puts down in writing: find that by adding 5% commercially available glucose or other sugar and sugar alcohol, for example 2.5% glycerol waits and oozes adjusting, can obtain the labile solution of Moxifloxacin during exploitation moxifloxacin hydrochloride injection.This instability shows in the solution and inferior visual granule (40 degree are deposited 4-8 and occurred after week) to occur, and reason is Moxifloxacin and or the triple role of its salt, ion and sugar or sugar alcohol.But, U.S. Patent application US6916484 provide be suitable as infusion solution contain sugar or sugar alcohol etc. ooze, can accept and the drug prescription of stable storage simultaneously.This prescription is very strict to the prescription as the sugar of osmotic pressure regulator and/or sugar alcohol, the numbers of poles of the transfusion iron content that requirement simultaneously is prepared into is low, therefore US6916484 is careful has made iron content and at least independently measures 6 times arithmetic mean of instantaneous value and meet≤20ppb, or the qualification of preferred 10ppb.The poor operability that this controls in suitability for industrialized production, and production cost height.And as the pharmacy worker, we know that condensation reaction at high temperature probably takes place amino aldehyde radical with glucose, moxifloxacin hydrochloride contains more weak amino, the active substance of moxifloxacin hydrochloride contacts with glucose for a long time in the large capacity transfusion, and the high temperature of terminal sterilization can aggravate the possibility of this condensation reaction, therefore, this kind infusion preparation causes that the risk of related substance increase is very big.Find in our research that after containing injection that active component is a moxifloxacin hydrochloride and placing some days with the glucose solution mix homogeneously, it is stable that quality keeps, clarity is variation not; But contain injection and the glucose solution mix homogeneously that active component is a moxifloxacin hydrochloride and new related substance promptly occurred behind 121 degree sterilization 15min, clarity is defective after 60 degree are placed one month.As seen contain injection that active component is a moxifloxacin hydrochloride and glucose solution at low temperatures in the short time compatibility be only stable.
We are for solving the above-mentioned drawback of moxifloxacin hydrochloride preparation, developed a kind of new moxifloxacin hydrochloride injection in conjunction with our discovering, its novelty outstanding behaviours has been equipped with special solvent containing the injection with small volume of moxifloxacin hydrochloride, high-capacity injection, concentrated solution for injection, injection freeze-dried powder, Injectable sterile freeze-dried powder.This special solvent just is used with the injection of active component as moxifloxacin hydrochloride before clinical the use.The reasonable use of this preparation combination, its unblamable figures in the expression of value of the linen, as an equivalent, and consequently, as a thing that is value have improved the stability of Moxifloxacin active component now effectively and have reduced the potential safety hazard of existing preparation.This special solvent self is very stable, and contains the Moxifloxacin formulations of active ingredients and separates preparation and preserve, and has heightened production efficiency and quality controllability effectively.The new moxifloxacin hydrochloride injection of our invention only needs not moxifloxacin hydrochloride active component and the special solvent mix homogeneously of specially joining before clinical use, be infused into human body in the 12h, can guarantee effectively that physiology etc. blends quality stability.We do the compatibility stability of the injection and the proprietary solvent 12h of persalt Moxifloxacin active component, and the result is as shown in table 2.
Table 2 moxifloxacin hydrochloride compatibility stability
Summary of the invention:
The claimed a kind of moxifloxacin hydrochloride injection of being furnished with special solvent of the present invention.This kind preparation comprises that the A active component is the combination of the injection and the B special solvent of moxifloxacin hydrochloride.
Moxifloxacin hydrochloride injection of the present invention is for sterilized powder or the aseptic concentrated solution of preparing or be diluted to solution or suspension before the clinical use, intravital sterile solution, emulsion or suspension be can inject, injection with small volume, high-capacity injection, concentrated solution for injection, injection freeze-dried powder, sterile powder for injection pin comprised.
Injection is meant that the confession that medicine is made is injected into sterile solution type injection, emulsion-type injection or the suspension type injection of using in the body, can be used for intravenous injection or intravenous drip etc.; Its labelled amount can be 1ml, 2ml, 5ml, 10ml, 20ml, 50ml, 100ml, 200ml, 250ml, 500ml etc., generally be not more than the injection with small volume that is called of 20ml, what be not less than 50ml is called high-capacity injection (the also title venous transfusion of using for intravenous drip).
Concentrated solution for injection means that confession that medicine is made faces the aseptic concentrated solution of using for intravenous drip with preceding dilution.
Injectable sterile powder means that confession that medicine is made is faced with the suitable sterile solution of preceding usefulness and is mixed with settled solution or the evenly sterilized powder or the aseptic block of suspension; Available suitable solvent for injection preparation back injection, also available venous transfusion preparation posterior vein instils; Can make with solvent crystallization, spray drying method or freeze-drying etc.
Moxifloxacin hydrochloride injection of the present invention can adopt conventional method production in the existing pharmaceutical field, can add various pharmaceutically acceptable additives in case of necessity.
The main component of special solvent of the present invention is one or more in glucose or other sugar or the sugar alcohol.Consumption when sugar in the special solvent of being joined or in the sugar alcohol one or more is 2% to 20% (w/v).
Preferred 5% to 10% (w/v) of consumption when the main component of special solvent of the present invention is in sugar or the sugar alcohol one or more.Sugar has sucrose, lactose, fructose, maltose etc. except that glucose, sugar alcohol has sorbitol, maltose alcohol, xylitol, lactose, glycerol.
Term " % (w/v) " refers to that unit of weight is the quantity of gram, i.e. g/100ml in per 100 ml volumes.
Special solvent of the present invention can adopt the conventional method production in the existing pharmaceutical field, except that adding above-mentioned sugar or sugar alcohol, also can add suitable additives, as osmotic pressure regulator, PH regulator, solubilizing agent, emulsifying agent, antioxidant, antibacterial, suspending agent etc.Osmotic pressure regulator sodium chloride commonly used, potassium chloride, magnesium chloride, calcium chloride etc., pH value regulator commonly used comprises hydrochloric acid, sulphuric acid, phosphoric acid, lactic acid, acetic acid-sodium acetate, citric acid-sodium citrate, sodium bicarbonate-sodium carbonate, sodium hydrogen phosphate-sodium dihydrogen phosphate etc.; Solubilizing agent, emulsifying agent commonly used comprise polyoxyethylene sorbitan monoleate, propylene glycol, lecithin, polyoxyethylene castor oil, polyvidone etc.; Antioxidant commonly used has sodium sulfite, sodium sulfite, sodium pyrosulfite, sodium thiosulfate etc.; Antibacterial commonly used is phenol, cresol, benzyl alcohol, chlorobutanol, hydroxypropyl butyl ester etc.; Suspending agent commonly used comprises methylcellulose, carboxymethyl cellulose, gelatin, pectin etc.
The special solvent that the further claimed moxifloxacin hydrochloride injection of the present invention is furnished with oozes application in the osmotic pressure regulating its physiology etc.After the moxifloxacin hydrochloride injection used the special solvent dilution of being joined, the osmotic pressure that can guarantee medicinal liquid had guaranteed the safety of clinical use in scope of normal human's colloidal osmotic pressure 285-320m0smol/kg and so on.
Below be the osmotic pressure data contrast before clinical use of commercially available moxifloxacin hydrochloride sodium chloride injection and the embodiment of the invention 1 injection, as shown in table 3:
Table 3 moxifloxacin hydrochloride injection osmotic pressure
The invention example:
The specific embodiment by the following examples is described in further detail foregoing of the present invention.But it is embodiment that the scope that this should be interpreted as the above-mentioned theme of the present invention only limits to following.All technology that realizes based on foregoing of the present invention all belong to category of the present invention.Adjuvant in following examples can be replaced with acceptable accessories, perhaps reduces, increases.
The preparation 1 of embodiment 1, moxifloxacin hydrochloride injection
Moxifloxacin hydrochloride injection (20ml: 400mg)
Prescription:
Moxifloxacin hydrochloride: 0.4Kg (in Moxifloxacin)
Water for injection: 20L
Preparation altogether: 1000
Preparation technology:
(1) will produce required ampoule cleans and aseptic process;
(2) 80% water for injection 50 degree insulations add the moxifloxacin hydrochloride stirring and dissolving;
(3) regulate PH to 5.0 with the sodium hydroxide solution of 0.5mol/l, benefit adds to the full amount of water for injection, and stirs;
(4) add the needle-use activated carbon of dosing amount 0.1%, stir 15min, filtering decarbonization;
(5) medicinal liquid is crossed the filter membrane fine straining of 0.45 μ m and 0.22 μ m respectively;
(6) measure intermediate, embedding after the assay was approved;
(7) 121 degree 15min flowing steam sterilizations;
(8) leak detection, lamp inspection;
(9) finished product is examined qualified back packing entirely.
Special solvent
Prescription 1 (5.4%):
Glucose: 12.5Kg
Water for injection: 230L
Preparation altogether: 1000
Prescription 2 (5.4%):
Mannitol: 12.5Kg
Water for injection: 230L
Preparation altogether: 1000
Preparation technology:
(1) will produce required injection bottle cleans and aseptic process;
The adjuvant stirring and dissolving that adds recipe quantity in (2) 80% the water for injection;
(3) benefit adds to the full amount of water for injection, and stirs;
(4) add the needle-use activated carbon of dosing amount 0.05%, stir 15min, filtering decarbonization;
(5) medicinal liquid is crossed the filter membrane fine straining of 0.45 μ m and 0.22 μ m respectively;
(6) measure intermediate, embedding after the assay was approved;
(7) 115 degree flowing steam sterilization 30min;
(8) leak detection, lamp inspection;
(9) finished product is examined qualified back packing entirely.
The preparation 2 of embodiment 2, moxifloxacin hydrochloride injection
Moxifloxacin hydrochloride injection (10ml: 200mg)
Prescription:
Moxifloxacin hydrochloride: 0.2Kg (in Moxifloxacin)
Water for injection: 10L
Preparation altogether: 1000
Preparation technology:
(1) will produce required cillin bottle and plug cleans and aseptic process;
(2) 80% water for injection 50 degree insulations add the moxifloxacin hydrochloride stirring and dissolving;
(3) regulate PH to 5.5 with the sodium hydroxide solution of 0.5mol/l, benefit adds to the full amount of water for injection, and stirs;
(4) add the needle-use activated carbon of dosing amount 0.05%, stir 20min, filtering decarbonization;
(5) medicinal liquid is crossed the filter membrane fine straining of 0.45 μ m and 0.22 μ m respectively;
(6) measure intermediate, embedding after the assay was approved;
(7) 115 degree 30min flowing steam sterilizations;
(8) leak detection, lamp inspection;
(9) finished product is examined qualified back packing entirely.
Special solvent: (2.8%)
Prescription:
Glycerol: 2.5Kg
Water for injection: 90L
Preparation altogether: 1000
Preparation technology: referring to embodiment 1
The preparation 3 of embodiment 3, moxifloxacin hydrochloride injection
Moxifloxacin hydrochloride injection (20ml: 400mg)
Prescription:
Moxifloxacin hydrochloride: 400g (in Moxifloxacin)
Calcium disodium edetate: 50g
Water for injection: 20L
Preparation altogether: 1000
Preparation technology:
(1) will produce required cillin bottle and plug cleans and aseptic process;
(2) 80% water for injection 50 degree insulations add the supplementary material stirring and dissolving;
(3) regulate PH to 5.0 with the sodium hydroxide solution of 0.5mol/l, benefit adds to the full amount of water for injection, and stirs;
(4) add the needle-use activated carbon of dosing amount 0.05%, stir 15min, filtering decarbonization;
(5) medicinal liquid is crossed the filter membrane fine straining of 0.45 μ m and 0.22 μ m respectively;
(6) medicinal liquid descended the filter membrane degerming of 0.22 μ m in gnotobasis;
(7) measure intermediate, fill after the assay was approved;
(8) finished product is examined qualified back packing entirely.
Special solvent: (10.9%)
Prescription:
Glucose: 12.5Kg
Sorbitol: 12.5Kg
Water for injection: 230L
Preparation altogether: 1000
Preparation technology: referring to embodiment 1
The preparation 1 of embodiment 4, hydrochloride for injection Moxifloxacin (lyophilized powder)
Hydrochloride for injection Moxifloxacin (0.4g)
Prescription:
Moxifloxacin hydrochloride: 400g (in Moxifloxacin)
Mannitol: 100g
Water for injection: 3000ml
Preparation altogether: 1000
Preparation technology:
(1) will produce used cillin bottle, plug and dosing clears up, degerming, removes thermal source with vessel, instrument and equipment etc.;
(2) mannitol and principal agent are added in the 50 degree waters for injection of dosing amount 80% stirring and dissolving respectively;
(3) regulate PH to 6.0 with the sodium hydroxide solution of 1.0mol/l, benefit adds to the full amount of water for injection, and stirs;
(4) needle-use activated carbon of adding dosing amount 0.05% stirs 15min, filters, and takes off charcoal;
(5) medicinal liquid is crossed the filter membrane fine straining of 0.45 μ m and 0.22 μ m respectively;
(6) the gained medicinal liquid is sub-packed in the 10ml control antibiotic cillin bottle every 3ml;
(7) vacuum lyophilization is jumped a queue, and rolls lid, the qualified back of product inspection packing.
Special solvent:
Prescription 1 (5.9%):
Glucose: 5Kg
Sodium chloride: 0.9Kg
Water for injection: 100L
Preparation altogether: 1000
Prescription 2 (5%):
Sorbitol: 12.5Kg
Water for injection: 250L
Preparation altogether: 1000
Preparation technology: referring to embodiment 1
The preparation 2 of embodiment 5, hydrochloride for injection Moxifloxacin (lyophilized powder)
Hydrochloride for injection Moxifloxacin (0.4g)
Prescription:
Moxifloxacin hydrochloride: 400g (in Moxifloxacin)
Mannitol: 100g
Sorbitol: 100g
Water for injection: 3000ml
Preparation altogether: 1000
Preparation technology: referring to embodiment 4
Special solvent:
Prescription: referring to embodiment 4
Preparation technology: referring to embodiment 1
The preparation of embodiment 6, hydrochloride for injection Moxifloxacin (aseptic powder)
Hydrochloride for injection Moxifloxacin (0.4g)
Prescription:
Moxifloxacin hydrochloride: 400g (in Moxifloxacin)
Preparation altogether: 1000
Preparation technology:
(1) will produce required antibiotic bottle and plug etc. cleans and aseptic process
(2) moxifloxacin hydrochloride 100 mesh sieves
(3) the moxifloxacin hydrochloride branch is packed in the antibiotic bottle, lid is rolled in tamponade.
(4) finished product is examined qualified back packing entirely.
Special solvent:
Prescription: referring to embodiment 4
Technology: referring to embodiment 1.
Claims (7)
1. new moxifloxacin hydrochloride injection.It is characterized in that comprising that the A active component is the combination of the injection and the B special solvent of moxifloxacin hydrochloride.
2. injection as claimed in claim 1 is characterized in that: described moxifloxacin hydrochloride injection can inject intravital sterile solution, emulsion or suspension for for sterilized powder or the aseptic concentrated solution of preparing or be diluted to solution or suspension before the clinical use.
3. injection as claimed in claim 2 is characterized in that: described moxifloxacin hydrochloride injection is injection with small volume, high-capacity injection, concentrated solution for injection, injection freeze-dried powder, sterile powder for injection pin.
4. injection as claimed in claim 1 is characterized in that: the main component of described special solvent is one or more in glucose or other sugar or the sugar alcohol.
5. injection as claimed in claim 4 is characterized in that: the consumption when sugar in the special solvent of being joined or in the sugar alcohol one or more is 2% to 20% (w/v).
6. injection as claimed in claim 5 is characterized in that: preferred 5% to 10% (w/v) of consumption when sugar in the special solvent of being joined or in the sugar alcohol one or more.
7. as the described arbitrary injection of claim 1～6, it is characterized in that: the special solvent of being furnished with oozes application in the osmotic pressure regulating moxifloxacin hydrochloride injection physiology etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100089740A CN102100666B (en) | 2011-01-17 | 2011-01-17 | New moxifloxacin hydrochloride injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100089740A CN102100666B (en) | 2011-01-17 | 2011-01-17 | New moxifloxacin hydrochloride injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102100666A true CN102100666A (en) | 2011-06-22 |
| CN102100666B CN102100666B (en) | 2012-07-18 |
Family
ID=44153866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100089740A Active CN102100666B (en) | 2011-01-17 | 2011-01-17 | New moxifloxacin hydrochloride injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102100666B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631316A (en) * | 2012-04-27 | 2012-08-15 | 天津红日药业股份有限公司 | Moxifloxacin injection preparation |
| CN102743383A (en) * | 2012-05-25 | 2012-10-24 | 南京恒通医药开发有限公司 | Stable moxifloxacin injection water-borne preparation |
| CN103239394A (en) * | 2013-04-01 | 2013-08-14 | 辽宁亿灵科创生物医药科技有限公司 | Small-volume moxifloxacin hydrochloride injection and preparation method thereof |
| CN103505407A (en) * | 2012-06-20 | 2014-01-15 | 四川科伦药业股份有限公司 | Multi-chamber bag packaged moxifloxacin hydrochloride/glucose aqueous solution preparation |
| CN107184547A (en) * | 2017-05-27 | 2017-09-22 | 江苏苏南药业实业有限公司 | Moxifloxacin hydrochloride injection for treating respiratory tract infection |
| CN109431987A (en) * | 2018-12-17 | 2019-03-08 | 江西润泽药业有限公司 | Moxifloxacin hydrochloride injection and preparation method thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368891A (en) * | 1999-08-06 | 2002-09-11 | 拜尔公司 | Moxilfloxacin formulation containing common salt |
| US6916484B1 (en) * | 1999-08-06 | 2005-07-12 | Bayer Aktiengesellschaft | Aqueous pharmaceutical composition containing moxifloxacin or salts thereof |
| CN1704057A (en) * | 2004-06-02 | 2005-12-07 | 上海医药科技发展有限公司 | Method for preparing lomefloxacin hydrochloride for injection |
| CN1726913A (en) * | 2004-07-30 | 2006-02-01 | 上海医药科技发展有限公司 | Powder and injection preparation of ciprofloxacin hydrochloride, and preparing method |
| CN1729977A (en) * | 2005-08-22 | 2006-02-08 | 吴祥根 | Freeze dry powdered injection of moxfloxacin or its salts and preparation process thereof |
| CN1729978A (en) * | 2005-08-30 | 2006-02-08 | 吴祥根 | Freeze dry powdered injection of moxlfloxacin or its salts and preparation process thereof |
| CN1751751A (en) * | 2005-09-07 | 2006-03-29 | 华北制药集团有限责任公司 | Immediate dispensing infusion |
| CN201119986Y (en) * | 2007-12-17 | 2008-09-24 | 山西天星制药有限公司 | Injection combination |
| CN101732246A (en) * | 2009-12-24 | 2010-06-16 | 济南百诺医药科技开发有限公司 | Moxifloxacin aqueous solution type injection |
| CN101836950A (en) * | 2010-03-12 | 2010-09-22 | 陕西合成药业有限公司 | Moxifloxacin hydrochloride glucose injection and preparation method and use thereof |
-
2011
- 2011-01-17 CN CN2011100089740A patent/CN102100666B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368891A (en) * | 1999-08-06 | 2002-09-11 | 拜尔公司 | Moxilfloxacin formulation containing common salt |
| US6916484B1 (en) * | 1999-08-06 | 2005-07-12 | Bayer Aktiengesellschaft | Aqueous pharmaceutical composition containing moxifloxacin or salts thereof |
| CN1704057A (en) * | 2004-06-02 | 2005-12-07 | 上海医药科技发展有限公司 | Method for preparing lomefloxacin hydrochloride for injection |
| CN1726913A (en) * | 2004-07-30 | 2006-02-01 | 上海医药科技发展有限公司 | Powder and injection preparation of ciprofloxacin hydrochloride, and preparing method |
| CN1729977A (en) * | 2005-08-22 | 2006-02-08 | 吴祥根 | Freeze dry powdered injection of moxfloxacin or its salts and preparation process thereof |
| CN1729978A (en) * | 2005-08-30 | 2006-02-08 | 吴祥根 | Freeze dry powdered injection of moxlfloxacin or its salts and preparation process thereof |
| CN1751751A (en) * | 2005-09-07 | 2006-03-29 | 华北制药集团有限责任公司 | Immediate dispensing infusion |
| CN201119986Y (en) * | 2007-12-17 | 2008-09-24 | 山西天星制药有限公司 | Injection combination |
| CN101732246A (en) * | 2009-12-24 | 2010-06-16 | 济南百诺医药科技开发有限公司 | Moxifloxacin aqueous solution type injection |
| CN101836950A (en) * | 2010-03-12 | 2010-09-22 | 陕西合成药业有限公司 | Moxifloxacin hydrochloride glucose injection and preparation method and use thereof |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631316A (en) * | 2012-04-27 | 2012-08-15 | 天津红日药业股份有限公司 | Moxifloxacin injection preparation |
| CN102631316B (en) * | 2012-04-27 | 2014-11-12 | 天津红日药业股份有限公司 | Moxifloxacin injection preparation |
| CN102743383A (en) * | 2012-05-25 | 2012-10-24 | 南京恒通医药开发有限公司 | Stable moxifloxacin injection water-borne preparation |
| CN103505407A (en) * | 2012-06-20 | 2014-01-15 | 四川科伦药业股份有限公司 | Multi-chamber bag packaged moxifloxacin hydrochloride/glucose aqueous solution preparation |
| CN103239394A (en) * | 2013-04-01 | 2013-08-14 | 辽宁亿灵科创生物医药科技有限公司 | Small-volume moxifloxacin hydrochloride injection and preparation method thereof |
| CN107184547A (en) * | 2017-05-27 | 2017-09-22 | 江苏苏南药业实业有限公司 | Moxifloxacin hydrochloride injection for treating respiratory tract infection |
| CN109431987A (en) * | 2018-12-17 | 2019-03-08 | 江西润泽药业有限公司 | Moxifloxacin hydrochloride injection and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102100666B (en) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102100666B (en) | New moxifloxacin hydrochloride injection | |
| CN102755296B (en) | Sterile lyophilized preparation containing fosaprepitant, and preparation method thereof | |
| JP2003506416A (en) | Moxifloxacin / sodium chloride preparation | |
| CN101961311B (en) | 5alpha-androstane (alkyl)-3beta,5,6beta-triol injection and preparation method thereof | |
| CN101011397A (en) | Pantoprazole sodium freeze dried injection and preparation method thereof | |
| CN101095659A (en) | Liposome combined medicine and method for preparing the same | |
| CN102716076B (en) | Ambroxol hydrochloride medicine combination for injection | |
| CN102860980A (en) | Method for preparing rocuronium bromide injection | |
| WO2010090765A2 (en) | Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products | |
| CN102481287B (en) | Pharmaceutical composition of temozolomide comprising vitamin c or vitamin c derivative and preparation method thereof | |
| CN102688183B (en) | A kind of stable moxifloxacin hydrochloride injection | |
| CN104784113B (en) | A kind of composition containing Linezolid and preparation method thereof | |
| CN102362855B (en) | Itraconazole isomer oral liquid | |
| CN102210686A (en) | Pharmaceutical composition containing ganciclovir compound, and preparation method thereof | |
| CN104606209A (en) | Compound vitamin medicine composition for injection and preparation method of compound vitamin medicine composition | |
| CN104940135A (en) | Fluconazole injection and preparation method thereof | |
| CN111465389B (en) | Pharmaceutical composition of docetaxel conjugate and preparation method thereof | |
| JPH0214058B2 (en) | ||
| CN103989640B (en) | Ornidazole intravenous administration preparation and preparation method | |
| CN101972257B (en) | A kind of pharmaceutical composition containing Moxifloxacin | |
| CN101129374B (en) | Vinflunine pharmaceutical composition and method of producing the same and application of the same | |
| CN105125505A (en) | Hydrochloric-acid tropisetron freeze-dried powder injection for injection and preparation method thereof | |
| CN1321997C (en) | Application of stable thiabutyldine quinoline carboxylate in preparing anti-infective | |
| CN113491668B (en) | Pharmaceutical composition preparation for injection and preparation method and application thereof | |
| CN103040737A (en) | Drug composition containing lansoprazole compound and preparation method of drug composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Applicant after: NANJING XINGANG MEDICAL Co.,Ltd. Co-applicant after: NANJING YOKO BIOMEDICAL R & D Ltd. Co-applicant after: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Address before: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Applicant before: NANJING XINGANG MEDICAL Co.,Ltd. Co-applicant before: Nanjing uniclever Biological Medicine Research Co.,Ltd. Co-applicant before: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Address after: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Applicant after: NANJING XINGANG MEDICAL Co.,Ltd. Co-applicant after: Nanjing uniclever Biological Medicine Research Co.,Ltd. Co-applicant after: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Address before: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Applicant before: NANJING XINGANG MEDICAL Co.,Ltd. Co-applicant before: NANJING ACEAN MEDICINE RESEARCH Co.,Ltd. Co-applicant before: NANJING ACEAN PHARMACEUTICAL Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: NANJING YOKO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: NANJING XINGANG MEDICINE CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee after: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee after: NANJING YOKO BIOMEDICAL R & D Ltd. Address before: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee before: NANJING XINGANG MEDICAL Co.,Ltd. Patentee before: NANJING YOKO BIOMEDICAL R & D Ltd. Patentee before: NANJING YOKO PHARMACEUTICAL Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee after: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee after: NANJING YOKO BIOMEDICAL R & D Ltd. Patentee after: NANJING YOKO BIOLOGICAL PHARMACEUTICAL GROUP Co.,Ltd. Address before: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee before: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee before: NANJING YOKO BIOMEDICAL R & D Ltd. Patentee before: Nanjing uniclever biological pharmaceutical Limited by Share Ltd. Address after: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee after: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee after: NANJING YOKO BIOMEDICAL R & D Ltd. Patentee after: Nanjing uniclever biological pharmaceutical Limited by Share Ltd. Address before: 210046 Nanjing economic and Technological Development Zone, Jiangsu Heng Road, No. 28 Patentee before: NANJING YOKO PHARMACEUTICAL Co.,Ltd. Patentee before: NANJING YOKO BIOMEDICAL R & D Ltd. |